Biosims making slow progress battling blockbusters for market share; FibroGen raising $300M

Spyros Papapetropoulos

Bloomberg has a report out today that illustrates just how slowly biosimilars are able to penetrate some of the world’s biggest franchises. Some say the market is tilted against them, with branded drugs winning and keeping preferred status, despite their higher costs.

⇨ FibroGen just joined the long line of public biotechs that have been cashing in on higher stock prices. The company is selling $300 million in shares after racking up some big gains.

⇨ Teva R&D exec Spyridon “Spyros” Papapetropoulos is joining Cavion as its new R&D chief. The little biotech has been working on new drugs that modulate the T-type calcium channel (Cav3) for the treatment of neurological diseases.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->